Accutest gets 21st US FDA approval

Accutest gets 21st US FDA approval

Accutest, the only independent clinical research organization (CRO), announced that US FDA has approved its 21st bio-study. This makes Accutest the only Indian CRO to have the largest number of FDA approvals. “21st US FDA approval is an indication of our commitment to Quality, Technology and Processes. It is the team work that has enabled us to achieve this honor,” said Dr. Satish Sawant, Director and founder Accutest India. Accutest Research Laboratories provides array of services and has its core expertise in BA/BE studies, Phase I to Phase IV Clinical Trials & Formulation development.

Dow, Colorcon join hands

Dow Chemical Company has tied up with Colorcon, Inc. for global sales, technical service and development, and distribution of Dow’s pharmaceutical excipient products for use in controlled release applications. The agreement applies to select METHOCEL hypro-mellose polymers, ETHOCEL ethylcellulose polymers and POLYOX poly(ethylene) oxide resins. This alliance fuses Dow’s expertise in excipient technology with Colorcon’s leadership in drug dosage formulation. Dow-Colorcon collaboration will make more technologically advanced excipients to the pharma market worldwide. Duo expects to develop the market for METHOCEL, ETHOCEL and POLYOX resins for controlled release applications. “This alliance is a natural outcome of our 28-year old cooperation. Together, we will meet the global demand of faster development and efficient production of drug ingredients,” said Philip Pilnik, commercial director for Dow Pharmaceutical Excipients. Jim Coward, VP & GM Colorcon Modified Release Technologies said, “The tie-up will speed up our new product development efforts, as well as improve existing solutions for controlled release.”